GenSci143 in Participants With Advanced Solid Tumors
ConditionAdvanced Solid Tumors
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorChangchun GeneScience Pharmaceutical Co., Ltd.
About this trial
A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of GenSci143 in Participants with Advanced Solid Tumors
Eligibility criteria
Qualifiers
Voluntarily sign the ICF.
Male or female participants ≥18 years old at the time of signing the ICF.
Dose escalation: Participants with histologically or cytologically documented recurrent or metastatic advanced solid tumors, and who have progressed after standard therapy, are intolerant to standard therapy, or have no standard therapy available.
Life expectancy of ≥ 12 weeks.
Disqualifiers
Participants with known spinal cord compression or active central nervous system (CNS) metastases, unless they are asymptomatic or have achieved post-treatment stability for >4 weeks and discontinued corticosteroids for >2 weeks before the first dose of GenSci143.
History of other known malignancies within the past 3 years.
Unstable thrombotic events requiring therapeutic intervention within 6 months before the first dose of GenSci143.
Uncontrolled or clinically significant cardiovascular disease.
Trial design
Treatments tested in this trial
- GenSci143 for injection
Treatment groups
180 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov